<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39558820</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2001-3078</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of extracellular vesicles</Title><ISOAbbreviation>J Extracell Vesicles</ISOAbbreviation></Journal><ArticleTitle>Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19.</ArticleTitle><Pagination><StartPage>e70001</StartPage><MedlinePgn>e70001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jev2.70001</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and has been related to more than 7 million deaths globally since 2019. The association of high levels of IL-6 with severe cases led to the early evaluation of the anti-IL6 inhibitor tocilizumab as a potential treatment, which unfortunately failed to improve survival in many trials. Moreover, little is known about the development of COVID-19 sequelae, and biomarkers are needed to understand and anticipate these processes. Because extracellular vesicles (EVs) play an important role in viral infection and immune response, they could potentially serve as predictive and prognostic biomarkers. We isolated EVs from 39 patients with severe COVID-19, from which 29 received tocilizumab and 10 were considered controls. Blood samples, which were collected at hospitalisation before treatment, at Day 7, and Day 15 during follow-up, were assessed by immunoblot for longitudinal expression of spike (S) and nucleocapsid (N) proteins. Dynamic expression was calculated and compared with clinicopathological and experimental variables. Expression of EV S was validated by immunogold and imaging flow-cytometry, revealing an enrichment in CD9+ EVs. As a result, decreasing expression of EV viral proteins was observed in patients treated with tocilizumab. Moreover, higher increase in EV S was observed in patients with lower antibody response, hyperfibrinogenemia, lower respiratory function, higher blood pressure and shorter outcomes. These findings lay the foundation for future studies characterizing the role of EVs in multiorgan assessment and identifying biomarkers in patients with severe COVID-19 and possible long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Journal of Extracellular Vesicles published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Miguel-Perez</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2822-4466</Identifier><AffiliationInfo><Affiliation>Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arroyo-Hernandez</LastName><ForeName>Marisol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Salvia</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunasekaran</LastName><ForeName>Muthukumar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Surgery and Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering</LastName><ForeName>Edward M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avila</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebru</LastName><ForeName>Etse</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becerril-Vargas</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Institute of Respiratory Diseases, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monraz-Perez</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Institute of Respiratory Diseases, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saharia</LastName><ForeName>Kapil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grazioli</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Program in Trauma, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCurdy</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0001-5319-0475</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frieman</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miorin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona</LastName><ForeName>Andr&#xe9;s F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Institute for Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Sastre</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaushal</LastName><ForeName>Sunjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Surgery and Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Fred R</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atanackovic</LastName><ForeName>Djordje</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahoo</LastName><ForeName>Susmita</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7279-1564</Identifier><AffiliationInfo><Affiliation>Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrieta</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Unit, Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolfo</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Medical Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54CA260560</GrantID><Agency>NCI-SERONET</Agency><Country/></Grant><Grant><GrantID>CEIRR</GrantID><Agency>NIAID-funded Center of Excellence for Influenza Research and Response</Agency><Country/></Grant><Grant><GrantID>75N93021C00014</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK125856</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL140469</GrantID><Agency>NIH-NHLBI</Agency><Country/></Grant><Grant><GrantID>R01HL148786</GrantID><Agency>NIH-NHLBI</Agency><Country/></Grant><Grant><GrantID>U19AI135972</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AI168631</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Evox Therapeutics, UK</Agency><Country/></Grant><Grant><Agency>CRIPT (Center for Research on Influenza Pathogenesis and Transmission)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Extracell Vesicles</MedlineTA><NlmUniqueID>101610479</NlmUniqueID><ISSNLinking>2001-3078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705834">nucleocapsid phosphoprotein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="Y">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">extracellular vesicles</Keyword><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">nucleocapsid</Keyword><Keyword MajorTopicYN="N">spike protein</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39558820</ArticleId><ArticleId IdType="doi">10.1002/jev2.70001</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>RECOVERY Collaborative Group. (2021). Tocilizumab in patients admitted to hospital with COVID&#x2010;19 (RECOVERY): A randomised, controlled, open&#x2010;label, platform trial. Lancet, 397, 1637&#x2013;1645.</Citation></Reference><Reference><Citation>Akpek, M. (2022). Does COVID&#x2010;19 cause hypertension? Angiology, 73, 682.</Citation></Reference><Reference><Citation>Atanackovic, D., Avila, S. V., Lutfi, F., de Miguel&#x2010;Perez, D., Fan, X., Sanchez&#x2010;Petitto, G., Vander Mause, E., Siglin, J., Baddley, J., Mannuel, H. D., Alkhaldi, H., Hankey, K. G., Lapidus, R., Kleinberg, M., Rabin, J., Shanholtz, C., Rolfo, C., Rapoport, A. P., Dahiya, S., &amp; Luetkens, T. (2021). Deep dissection of the antiviral immune profile of patients with COVID&#x2010;19. Communications biology, 4, 1389.</Citation></Reference><Reference><Citation>Balbi, C., Burrello, J., Bolis, S., Lazzarini, E., Biemmi, V., Pianezzi, E., Burrello, A., Caporali, E., Grazioli, L. G., Martinetti, G., Fusi&#x2010;Schmidhauser, T., Vassalli, G., Melli, G., &amp; Barile, L. (2021). Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS&#x2010;CoV&#x2010;2 infection. EBioMedicine, 67, 103369.</Citation></Reference><Reference><Citation>Bansal, S., Perincheri, S., Fleming, T., Poulson, C., Tiffany, B., Bremner, R. M., &amp; Mohanakumar, T. (2021). Cutting edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer&#x2010;BioNTech) vaccination prior to development of antibodies: A novel mechanism for immune activation by mRNA vaccines. Journal of immunology, 207, 2405&#x2013;2410.</Citation></Reference><Reference><Citation>Buzas, E. I. (2022). The roles of extracellular vesicles in the immune system. Nature Reviews Immunology, 23, 236&#x2013;250.</Citation></Reference><Reference><Citation>Buzas, E. I., Gy&#xf6;rgy, B., Nagy, G., Falus, A., &amp; Gay, S. (2014). Emerging role of extracellular vesicles in inflammatory diseases. Nature Reviews Rheumatology, 10, 356&#x2013;364.</Citation></Reference><Reference><Citation>Chen, X., Li, H., Song, H., Wang, J., Zhang, X., Han, P., &amp; Wang, X. (2022). Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS&#x2010;CoV&#x2010;2. Journal of Extracellular Vesicles, 11, e12288.</Citation></Reference><Reference><Citation>Craddock, V., Mahajan, A., Spikes, L., Krishnamachary, B., Ram, A. K., Kumar, A., Chen, L., Chalise, P., &amp; Dhillon, N. K. (2023). Persistent circulation of soluble and extracellular vesicle&#x2010;linked Spike protein in individuals with postacute sequelae of COVID&#x2010;19. Journal of Medical Virology, 95, e28568.</Citation></Reference><Reference><Citation>de Miguel&#x2010;Perez, D., Ortega, F. G., Tejada, R. G., Mart&#xed;nez&#x2010;&#xda;nica, A., Peterson, C. B., Russo, A., Gunasekaran, M., Cardona, A. F., Amezcua, V., Lorente, J. A., Exp&#xf3;sito Hern&#xe1;ndez, J., Rolfo, C., &amp; Serrano, M. J. (2023). Baseline extracellular vesicle miRNA&#x2010;30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. Biomarker Research, 11, 98.</Citation></Reference><Reference><Citation>de Miguel&#x2010;Perez, D., Russo, A., Arrieta, O., Ak, M., Barron, F., Gunasekaran, M., Mamindla, P., Lara&#x2010;Mejia, L., Peterson, C. B., Er, M. E., Peddagangireddy, V., Buemi, F., Cooper, B., Manca, P., Lapidus, R. G., Hsia, R. C., Cardona, A. F., Naing, A., Kaushal, S., &#x2026; Rolfo, C. (2022). Extracellular vesicle PD&#x2010;L1 dynamics predict durable response to immune&#x2010;checkpoint inhibitors and survival in patients with non&#x2010;small cell lung cancer. Journal of Experimental &amp; Clinical Cancer Research : CR, 41, 1&#x2013;14.</Citation></Reference><Reference><Citation>de Miguel&#x2010;Perez, D., Russo, A., Gunasekaran, M., Buemi, F., Hester, L., Fan, X., Carter&#x2010;Cooper, B. A., Lapidus, R. G., Peleg, A., Arroyo&#x2010;Hern&#xe1;ndez, M., Cardona, A. F., Naing, A., Hirsch, F. R., Mack, P. C., Kaushal, S., Serrano, M. J., Adamo, V., Arrieta, O., &amp; Rolfo, C. (2023). Baseline extracellular vesicle TGF&#x2010;&#x3b2; is a predictive biomarker for response to immune checkpoint inhibitors and survival in non&#x2010;small cell lung cancer. Cancer, 129, 521&#x2013;530.</Citation></Reference><Reference><Citation>Deng, X. J., Tang, K., Wang, Z., He, S., &amp; Luo, Z. (2024). Impacts of inflammatory cytokines variants on systemic inflammatory profile and COVID&#x2010;19 severity. Journal of Epidemiology and Global Health, 14(2), 363&#x2013;378. https://doi.org/10.1007/S44197&#x2010;024&#x2010;00204&#x2010;W</Citation></Reference><Reference><Citation>Du, H., Du, Z., Wang, L., Wang, H., Jia, M., Zhang, C., Liu, Y., Zhang, C., Zhang, Y., Zhang, R., Zhang, S., Zhang, N., Ma, Z., Chen, C., Liu, W., Zeng, H., Gao, G. F., Hou, X., &amp; Bi, Y. (2024). Fulminant myocarditis induced by SARS&#x2010;CoV&#x2010;2 infection without severe lung involvement: Insights into COVID&#x2010;19 pathogenesis. Journal of Genetics and Genomics, 51, 608&#x2013;616.</Citation></Reference><Reference><Citation>Earnest, J. T., Hantak, M. P., Li, K., McCray, P. B. Jr, Perlman, S., &amp; Gallagher, T. (2017). The tetraspanin CD9 facilitates MERS&#x2010;coronavirus entry by scaffolding host cell receptors and proteases. PLoS pathogens, 13(7), e1006546.</Citation></Reference><Reference><Citation>Fitzgerald, W., Freeman, M. L., Lederman, M. M., Vasilieva, E., Romero, R., &amp; Margolis, L. (2018). A system of cytokines encapsulated in extracellular vesicles. Scientific Reports, 8, 1&#x2013;11.</Citation></Reference><Reference><Citation>George, M. S., Sanchez, J., Rollings, C., Fear, D., Irving, P., Sinclair, L. V., &amp; Schurich, A. (2023). Extracellular vesicles in COVID&#x2010;19 convalescence can regulate T cell metabolism and function. Iscience, 26, 107280.</Citation></Reference><Reference><Citation>Gerard, L., Lecocq, M., Bouzin, C., Hoton, D., Schmit, G., Pereira, J. P., Montiel, V., Plante&#x2010;Bordeneuve, T., Laterre, P. F., &amp; Pilette, C. (2021). Increased angiotensin&#x2010;converting enzyme 2 and loss of alveolar Type II cells in COVID&#x2010;19&#x2010;related acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 204, 1024&#x2013;1034.</Citation></Reference><Reference><Citation>REMAP&#x2010;CAP Investigators. Gordon, A. C., Mouncey, P. R., Al&#x2010;Beidh, F., Rowan, K. M., Nichol, A. D., Arabi, Y. M., Annane, D., Beane, A., van Bentum&#x2010;Puijk, W., Berry, L. R., Bhimani, Z., Bonten, M. J. M., Bradbury, C. A., Brunkhorst, F. M., Buzgau, A., Cheng, A. C., Detry, M. A., Duffy, E. J., Estcourt, L. J., &#x2026; Derde, L. P. G.. (2021). Interleukin&#x2010;6 receptor antagonists in critically ill patients with Covid&#x2010;19. The New England Journal of Medicine, 384, 1491&#x2013;1502.</Citation></Reference><Reference><Citation>Groff, D., Sun, A., Ssentongo, A. E., Ba, D. M., Parsons, N., Poudel, G. R., Lekoubou, A., Oh, J. S., Ericson, J. E., Ssentongo, P., &amp; Chinchilli, V. M. (2021). Short&#x2010;term and long&#x2010;term rates of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection: A systematic review. JAMA Network Open, 4(10), e2128568.</Citation></Reference><Reference><Citation>Hassanpour, M., Rezaie, J., Nouri, M., &amp; Panahi, Y. (2020). The role of extracellular vesicles in COVID&#x2010;19 virus infection. Infection, Genetics and Evolution, 85, 104422.</Citation></Reference><Reference><Citation>He, T., Ling, J., &amp; Yang, J. (2023). Tocilizumab&#x2010;induced hypofibrinogenemia in patients with systemic&#x2010;onset juvenile idiopathic arthritis. Scientific Reports, 13, 9050.</Citation></Reference><Reference><Citation>Krishnamachary, B., Cook, C., Kumar, A., Spikes, L., Chalise, P., &amp; Dhillon, N. K. (2021). Extracellular vesicle&#x2010;mediated endothelial apoptosis and EV&#x2010;associated proteins correlate with COVID&#x2010;19 disease severity. Journal of Extracellular Vesicles, 10(9), e12117.</Citation></Reference><Reference><Citation>Lannigan, J., &amp; Erdbruegger, U. (2017). Imaging flow cytometry for the characterization of extracellular vesicles. Methods, 112, 55&#x2013;67.</Citation></Reference><Reference><Citation>Nahkuri, S., Becker, T., Schueller, V., Massberg, S., &amp; Bauer&#x2010;Mehren, A. (2021). Prior fluid and electrolyte imbalance is associated with COVID&#x2010;19 mortality. Communications Medicine, 1, 51.</Citation></Reference><Reference><Citation>Parotto, M., Gy&#xf6;ngy&#xf6;si, M., Howe, K., Myatra, S. N., Ranzani, O., Shankar&#x2010;Hari, M., &amp; Herridge, M. S. (2023). Post&#x2010;acute sequelae of COVID&#x2010;19: understanding and addressing the burden of multisystem manifestations. The Lancet Respiratory Medicine, 11(8), 739&#x2013;754.</Citation></Reference><Reference><Citation>Pesce, E., Manfrini, N., Cordiglieri, C., Santi, S., Bandera, A., Gobbini, A., Gruarin, P., Favalli, A., Bombaci, M., Cuomo, A., Collino, F., Cricr&#xec;, G., Ungaro, R., Lombardi, A., Mangioni, D., Muscatello, A., Aliberti, S., Blasi, F., Gori, A., &#x2026; Grifantini, R. (2022). Exosomes recovered from the plasma of COVID&#x2010;19 patients expose SARS&#x2010;CoV&#x2010;2 spike&#x2010;derived fragments and contribute to the adaptive immune response. Frontiers in Immunology, 12, 785941.</Citation></Reference><Reference><Citation>Rautaniemi, K., Zini, J., L&#xf6;fman, E., Saari, H., Haapalehto, I., Laukka, J., Vesam&#xe4;ki, S., Efimov, A., Yliperttula, M., Laaksonen, T., Vuorimaa&#x2010;Laukkanen, E., &amp; Lisitsyna, E. S. (2021). Addressing challenges in the removal of unbound dye from passively labelled extracellular vesicles. Nanoscale Advances, 4, 226.</Citation></Reference><Reference><Citation>Rosas, I. O., Br&#xe4;u, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., Savic, S., Youngstein, T., Del Sorbo, L., Cubillo Gracian, A., De La Zerda, D. J., Ustianowski, A., Bao, M., Dimonaco, S., Graham, E., &#x2026; Malhotra, A. (2021). Tocilizumab in hospitalized patients with severe Covid&#x2010;19 pneumonia. The New England Journal of Medicine, 384, 1503&#x2013;1516.</Citation></Reference><Reference><Citation>Roy, B., &amp; Runa, S. A. (2022). SARS&#x2010;CoV&#x2010;2 infection and diabetes: Pathophysiological mechanism of multi&#x2010;system organ failure. World Journal of Virology, 11, 252.</Citation></Reference><Reference><Citation>Rushworth, C. A., Guy, J. L., &amp; Turner, A. J. (2008). Residues affecting the chloride regulation and substrate selectivity of the angiotensin&#x2010;converting enzymes (ACE and ACE2) identified by site&#x2010;directed mutagenesis. The FEBS Journal, 275, 6033.</Citation></Reference><Reference><Citation>Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan&#x2010;Lewis, E., Baden, R., Pandit, L., Cameron, M. L., Garcia&#x2010;Diaz, J., Ch&#xe1;vez, V., Mekebeb&#x2010;Reuter, M., Lima de Menezes, F., Shah, R., Gonz&#xe1;lez&#x2010;Lara, M. F., Assman, B., Freedman, J., &amp; Mohan, S. V. (2021). Tocilizumab in patients hospitalized with Covid&#x2010;19 pneumonia. The New England Journal of Medicine, 384, 20&#x2013;30.</Citation></Reference><Reference><Citation>Somiya, M. (2022). Comment on &#x2018;cutting edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 (Pfizer&#x2010;BioNTech) vaccination prior to development of antibodies: A novel mechanism for immune activation by mRNA vaccines&#x2019;. Journal of Immunology, 208, 1833&#x2013;1833.</Citation></Reference><Reference><Citation>Sweet, D. R., Freeman, M. L., &amp; Zidar, D. A. (2023). Immunohematologic biomarkers in COVID&#x2010;19: Insights into pathogenesis, prognosis, and prevention. Pathogens &amp; Immunity, 8, 17&#x2013;50.</Citation></Reference><Reference><Citation>Tertel, T., Tomi&#x107;, S., &#x110;oki&#x107;, J., Radojevi&#x107;, D., Stevanovi&#x107;, D., Ili&#x107;, N., Giebel, B., &amp; Kosanovi&#x107;, M. (2022). Serum&#x2010;derived extracellular vesicles: Novel biomarkers reflecting the disease severity of COVID&#x2010;19 patients. Journal of Extracellular Vesicles, 11, e12257.</Citation></Reference><Reference><Citation>Troyer, Z., Alhusaini, N., Tabler, C. O., Sweet, T., de Carvalho, K. I. L., Schlatzer, D. M., Carias, L., King, C. L., Matreyek, K., &amp; Tilton, J. C. (2021). Extracellular Vesicles Carry SARS&#x2010;CoV&#x2010;2 Spike Protein and Serve as Decoys for Neutralizing Antibodies. Journal of Extracellular Vesicles, 10, e12112.</Citation></Reference><Reference><Citation>Welsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., Cai, H., Di Vizio, D., Driedonks, T. A. P., Erdbr&#xfc;gger, U., Falcon&#x2010;Perez, J. M., Fu, Q. L., Hill, A. F., Lenassi, M., Lim, S. K., Mahoney, M. G., Mohanty, S., M&#xf6;ller, A., Nieuwland, R., &#x2026; Witwer, K. W. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 13, e12404.</Citation></Reference><Reference><Citation>Xia, B., Pan, X., Luo, R. H., Shen, X., Li, S., Wang, Y., Zuo, X., Wu, Y., Guo, Y., Xiao, G., Li, Q., Long, X. Y., He, X. Y., Zheng, H. Y., Lu, Y., Pang, W., Zheng, Y. T., Li, J., Zhang, L. K., &amp; Gao, Z. (2023). Extracellular vesicles mediate antibody&#x2010;resistant transmission of SARS&#x2010;CoV&#x2010;2. Cell Discovery, 9, 2.</Citation></Reference><Reference><Citation>Zhang, V., Fisher, M., Hou, W., Zhang, L., &amp; Duong, T. Q. (2023). Incidence of New&#x2010;onset hypertension post&#x2010;COVID&#x2010;19: Comparison with influenza. Hypertension, 80, 2135&#x2013;2148.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>